Cite
The Efficacy of Immune Checkpoint Inhibitors vs. Chemotherapy for KRAS-Mutant or EGFR-Mutant Non-Small-Cell Lung Cancers: A Meta-Analysis Based on Randomized Controlled Trials.
MLA
Chen, Wei, et al. “The Efficacy of Immune Checkpoint Inhibitors vs. Chemotherapy for KRAS-Mutant or EGFR-Mutant Non-Small-Cell Lung Cancers: A Meta-Analysis Based on Randomized Controlled Trials.” Disease Markers, Aug. 2022, pp. 1–11. EBSCOhost, https://doi.org/10.1155/2022/2631852.
APA
Chen, W., Li, L., Cheng, S., & Yu, J. (2022). The Efficacy of Immune Checkpoint Inhibitors vs. Chemotherapy for KRAS-Mutant or EGFR-Mutant Non-Small-Cell Lung Cancers: A Meta-Analysis Based on Randomized Controlled Trials. Disease Markers, 1–11. https://doi.org/10.1155/2022/2631852
Chicago
Chen, Wei, Ling Li, Sheng Cheng, and Junxian Yu. 2022. “The Efficacy of Immune Checkpoint Inhibitors vs. Chemotherapy for KRAS-Mutant or EGFR-Mutant Non-Small-Cell Lung Cancers: A Meta-Analysis Based on Randomized Controlled Trials.” Disease Markers, August, 1–11. doi:10.1155/2022/2631852.